Comera Life Sciences Holdings, Inc. (NASDAQ:CMRA – Get Rating) was the target of a large drop in short interest during the month of December. As of December 30th, there was short interest totalling 174,600 shares, a drop of 11.6% from the December 15th total of 197,600 shares. Based on an average daily volume of 77,200 shares, the short-interest ratio is presently 2.3 days. Currently, 1.8% of the company's shares are short sold.
Comera Life Sciences Price Performance
CMRA stock traded down $0.07 during midday trading on Friday, hitting $1.40. The stock had a trading volume of 59,692 shares, compared to its average volume of 171,715. The business has a fifty day moving average price of $1.39 and a two-hundred day moving average price of $1.87. Comera Life Sciences has a 1-year low of $1.11 and a 1-year high of $11.44.
Get Comera Life Sciences alerts:Comera Life Sciences (NASDAQ:CMRA – Get Rating) last released its earnings results on Thursday, November 10th. The company reported ($0.20) EPS for the quarter. The company had revenue of $0.24 million during the quarter.
Insider Buying and Selling
In related news, major shareholder David Soane purchased 202,701 shares of the firm's stock in a transaction dated Wednesday, January 4th. The stock was bought at an average price of $1.23 per share, with a total value of $249,322.23. Following the completion of the purchase, the insider now owns 3,336,562 shares in the company, valued at approximately $4,103,971.26. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 4.50% of the stock is owned by corporate insiders.Institutional Trading of Comera Life Sciences
Several hedge funds have recently modified their holdings of the stock. Bluefin Capital Management LLC bought a new stake in Comera Life Sciences in the second quarter valued at $73,000. Jane Street Group LLC acquired a new position in Comera Life Sciences during the 2nd quarter worth approximately $115,000. Arena Investors LP acquired a new stake in Comera Life Sciences in the third quarter valued at approximately $137,000. Virtu Financial LLC bought a new stake in shares of Comera Life Sciences during the third quarter valued at approximately $25,000. Finally, Lake Street Advisors Group LLC raised its position in shares of Comera Life Sciences by 216.5% during the third quarter. Lake Street Advisors Group LLC now owns 316,469 shares of the company's stock worth $510,000 after purchasing an additional 216,469 shares during the period. Institutional investors own 2.94% of the company's stock.
Comera Life Sciences Company Profile
(Get Rating)
Comera Life Sciences Holdings, Inc, a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions.
Read More
- Get a free copy of the StockNews.com research report on Comera Life Sciences (CMRA)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
Receive News & Ratings for Comera Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Comera Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.